New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ: BIIB) concerning potential violations of the federal securities laws.

The stock fell sharply on heavy volume following the May 14 topline data release. Biogen had previously signaled confidence in its pipeline during its Q1 2025 earnings call, with management stating they expected to see data from BIIB080 in early Alzheimer's disease sometime around mid-year." The CELIA trial did not achieve statistical significance on its primary endpoint. The magnitude of the single-session decline reflected the market's reassessment of Biogen's near-term pipeline value.

If you suffered a loss on your Biogen Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297675

Source: Levi & Korsinsky, LLP